Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Dana-Farber Cancer Institute

    - PMLiVE

    Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

    The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

    - PMLiVE

    Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients

    The drug is already approved in the UK to treat advanced cases of the disease

    - PMLiVE

    ICR researchers uncover genes responsible for tumour progression in prostate cancer

    The findings could pave the way for new treatment approaches that improve patient outcomes

    - PMLiVE

    ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

    The research could pave the way for the development of new drugs that prevent drug resistance

    - PMLiVE

    Novartis’ Kisqali receives EC approval to treat early breast cancer patients

    Approximately 70% of breast cancer cases are diagnosed in the early stages of the disease

    - PMLiVE

    ICR researchers identify potential treatment approach for acute myeloid leukaemia

    More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year

    - PMLiVE

    Novartis’ Kisqali receives CHMP recommendation for early breast cancer patients

    Approximately 70% of all breast cancer patients have HR-positive/HER2-negative disease

    - PMLiVE

    ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients

    More than 130,000 patients are treated with radiotherapy on the NHS every year

    - PMLiVE

    ICR researchers identify new drug target for advanced prostate cancer patients

    The team estimates that around 10% of patients have high levels of the BCL2 protein

    - PMLiVE

    Novartis’ Kisqali combination granted FDA approval for early breast cancer patients

    The drug is already approved for certain cases of advanced or metastatic breast cancer

    - PMLiVE

    Breast cancer drug found to help slow growth of rare childhood brain tumour

    Researchers discovered that targeting the CDK6 protein could make tumour cells vulnerable to treatment

    - PMLiVE

    UK study reveals previously unknown genetic causes of colorectal cancer

    The third most commonly diagnosed cancer globally is responsible for more than 44,000 new cases in the UK every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links